Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

@article{Serrate2009DiethylstilbestrolR,
  title={Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.},
  author={Camille Serrate and Yohann Loriot and Thibault de la Motte Rouge and Marine Gross-Goupil and Christophe C Massard and Bernard Escudier and Alberto Bossi and Karim S Fizazi},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2009},
  volume={20 5},
  pages={965}
}
Docetaxel-based chemotherapy is currently the standard treatment for metastatic castration-resistant prostate cancer (CRPC). Two large randomized studies demonstrated that this treatment prolongs survival and also improves time-to-disease progression, pain control and prostate-specific antigen (PSA) response, as compared with mitoxantrone and prednisone [1, 2]. However, patients eventually experience cancer progression within several months and there is currently no established standard… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…